Reposted by Neil Conlon
BREAKING: The #FDA has approved datopotamab deruxtecan (Dato-DXd) for the treatment of patients with unresectable or metastatic HR+/HER2- breast cancer who have received prior systemic therapy. #bcsm
www.targetedonc.com/view/fda-app...
targetedonc.com
FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.
